Compare GEO & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEO | DYN |
|---|---|---|
| Founded | 1984 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.8B |
| IPO Year | 1996 | 2020 |
| Metric | GEO | DYN |
|---|---|---|
| Price | $32.24 | $26.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $39.67 | $37.00 |
| AVG Volume (30 Days) | 1.7M | ★ 1.9M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 727.27 | N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $2,263,420,000.00 | N/A |
| Revenue This Year | $13.74 | N/A |
| Revenue Next Year | $9.99 | N/A |
| P/E Ratio | $49.51 | ★ N/A |
| Revenue Growth | ★ 3.85 | N/A |
| 52 Week Low | $12.51 | $11.92 |
| 52 Week High | $33.15 | $27.31 |
| Indicator | GEO | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 59.91 | 58.99 |
| Support Level | $28.79 | $16.45 |
| Resistance Level | $32.30 | $26.96 |
| Average True Range (ATR) | 1.36 | 0.91 |
| MACD | 0.06 | -0.16 |
| Stochastic Oscillator | 78.87 | 59.35 |
The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services. The company operates in U.S, Australia and South Africa.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.